Ir a la página de inicio del Gobierno del Principado de Asturias

Datos del Documento

Utilice este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/10947


Título: Ig-like transcript 2 (ILT2) blockade and lenalidomide restore NK cell function in Chronic Lymphocytic Leukemia
Autores: Villa, Mónica
Sordo-Bahamonde, Christian
Lorenzo-Herrero, Seila
Gonzalez-Rodríguez, Ana Pilar
Rodríguez-Payer, Ángel
González-García, Esther
López-Soto, Alejandro
González, Segundo
Palabras Claves: chronic lymphocytic leukemia
Checkpoints
NK cells
ILT2
lenalidomide
IL-2
Fecha Edición: 11-Dic-2018
Editor: Anahid Jewett, University of California
Cita Bibliográfica: Villa-Álvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Payer AR, Gonzalez-Garcia E, Villa-Álvarez MC, López-Soto A and Gonzalez S (2018) Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia. Front. Immunol. 9:2917. doi: 10.3389/fimmu.2018.02917
Resumen: One of the cardinal features of chronic lymphocytic leukemia (CLL) is its association with a profound immunosuppression. NK cell function is markedly impaired in CLL patients, who show a significant dysregulation of the expression of activating and inhibitory receptors. Here, we analyzed the role of the novel inhibitory receptor Ig-like transcript 2 (ILT2, also termed LIR-1, LILRB1) in the regulation of NK cells in CLL. Our results show that ILT2 expression was significantly decreased on leukemic cells and increased on NK cells of CLL patients, particularly in those with advanced disease and with bad prognostic features, such as those carrying chromosome del(11q). The immunomodulatory drug lenalidomide may regulate the expression of ILT2 and its ligands in CLL since it significantly increased the expression of ILT2 and partially reestablished the expression of its ligands on leukemic cells. Furthermore, lenalidomide significantly increased the activation and proliferation of NK cells, which was strongly enhanced by ILT2 blockade. Combining ILT2 blockade and lenalidomide activated NK cell cytotoxicity resulting in increased elimination of leukemic cells from CLL patients. Overall, we describe herein the role of an inhibitory receptor involved in the suppression of NK cell activity in CLL, which is restored by ILT2 blockade in combination with lenalidomide, suggesting that it may be an interesting therapeutic strategy to be explored in this disease.
URI: https://ria.asturias.es/RIA/handle/123456789/10947
ISSN: 1664-3224
Aparece en las Colecciones:Sanidad

Archivos en este documento:



Archivo TamañoFormato
fimmu-09-02917.pdf1,94 MBAdobe PDFVer/Abrir



logo

Todos los documentos en RIA están protegidos por derechos de autor.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Contacto